Urge Urinary Incontinence (Overactive Bladder)

1. Clinical Overview

Summary

Urge urinary incontinence (UUI) is the involuntary leakage of urine accompanied by or immediately preceded by a sudden, compelling desire to void that is difficult to defer (urgency). UUI is a key component of overactive bladder (OAB) syndrome, which encompasses urgency with or without incontinence, usually accompanied by frequency and nocturia, in the absence of proven infection or other obvious pathology. [1,2]

The underlying pathophysiology involves detrusor overactivity—involuntary detrusor contractions during the bladder filling phase. OAB affects approximately 12-17% of the adult population worldwide and has a profound impact on quality of life, psychological wellbeing, sexual function, and work productivity. [3,4]

Key Facts

Clinical Pearls

Clinical Pearl: OAB "Wet" vs "Dry": OAB syndrome may present as "wet" (with urge incontinence) affecting ~33-66% of OAB patients, or "dry" (urgency and frequency without leakage). This distinction matters for patient counselling and treatment expectations. [5]

Clinical Pearl: Neurological Red Flags: Always screen for neurological causes—ask specifically about back pain, saddle anaesthesia, leg weakness, and numbness. Cauda equina syndrome can present with new-onset urge incontinence. [6]

Clinical Pearl: Anticholinergic Burden in Elderly: Exercise extreme caution when prescribing anticholinergics to patients > 65 years. Cumulative anticholinergic burden is associated with increased risk of cognitive impairment and dementia. Consider mirabegron as first-line in this population. [7,8]

Clinical Pearl: Bladder Diary is Diagnostic: A 3-day bladder diary is the single most valuable investigation. It objectively documents frequency (> 8 voids/day), nocturia (≥2 episodes/night), voided volumes, and incontinence episodes. Essential before starting any treatment. [9]

Clinical Pearl: Mixed Incontinence is Common: Up to 30-40% of women have mixed stress and urge incontinence. Treat the predominant symptom first. If urgency predominates, start with OAB management. [10]

---

2. Epidemiology

Prevalence and Incidence

Overactive bladder is a highly prevalent condition with significant variation by age, sex, and geography.

Exam Detail: Examination Focus: The EPIC study (2006) surveyed > 19,000 adults across 5 countries and found OAB prevalence of 11.8% overall, with similar rates in men (10.7%) and women (12.8%). Prevalence increased from 4% in those aged 18-24 to 31% in those > 65 years. [3] This is a landmark epidemiological study frequently cited in MRCOG examinations.

Risk Factors

Quality of Life Impact

OAB has a profound impact on multiple domains of life, comparable to chronic conditions like diabetes, heart disease, and depression. [13]

Documented Impacts:

• Work Productivity: 30-40% report decreased work performance; 10-15% consider quitting jobs
• Social Activities: 50-60% avoid social situations; fear of odour and embarrassment
• Sexual Function: 40-50% report impaired sexual relationships
• Sleep Disruption: Nocturia ≥2 episodes/night associated with fragmented sleep, daytime fatigue
• Mental Health: 2-3× increased risk of depression and anxiety disorders [14]
• Fall Risk: Elderly patients rushing to toilet have 2-fold increased fall risk

---

3. Aetiology and Pathophysiology

Normal Micturition Physiology

Understanding normal bladder control is essential to grasp OAB pathophysiology.

STORAGE PHASE (Sympathetic Control)
↓
Detrusor Relaxation (β3-adrenergic receptors)
+ Urethral Sphincter Contraction (α-adrenergic)
↓
Bladder Fills (250-400ml capacity)
↓
First Sensation (~150ml) → Fullness (~300ml)
↓
VOLUNTARY DECISION TO VOID
↓
VOIDING PHASE (Parasympathetic Control)
↓
Pontine Micturition Centre Activation
↓
Detrusor Contraction (M3 muscarinic receptors)
+ Urethral Sphincter Relaxation
↓
Complete Bladder Emptying (less than 50ml residual)

Key Neural Pathways:

• Pontine Micturition Centre (PMC): Coordinates voiding reflex
• Sacral Micturition Centre (S2-S4): Parasympathetic innervation
• Sympathetic (T10-L2): Storage phase control
• Somatic (S2-S4, Pudendal Nerve): Voluntary external sphincter control

Pathophysiology of Detrusor Overactivity

Exam Detail: Detrusor overactivity (DO) is characterized by involuntary detrusor contractions during the filling phase, which may be spontaneous or provoked. These contractions create urgency and, if the patient cannot voluntarily suppress them, result in urge incontinence.

Proposed Mechanisms (Multiple Pathways):

1. Myogenic Hypothesis

• Partial Denervation: Neurological injury leads to scattered denervated smooth muscle cells
• Supersensitivity: Denervated cells become hypersensitive to acetylcholine and develop spontaneous activity
• Gap Junction Coupling: Abnormal electrical coupling between smooth muscle cells allows propagation of spontaneous contractions [15]
• Supporting Evidence: Increased expression of connexin-43 (gap junction protein) in OAB bladders

2. Neurogenic Hypothesis

• Loss of Central Inhibition: Damage to pontine-sacral pathways (e.g., in MS, stroke) reduces voluntary control
• Primitive Reflex Emergence: Uninhibited sacral reflex arcs cause involuntary voiding
• C-Fibre Afferent Sensitization: Normally silent C-fibres become mechanosensitive, triggering premature voiding reflexes [16]

3. Urotherial/Afferent Hypothesis

• Urothelial Dysfunction: Altered release of neurotransmitters (ATP, acetylcholine, nitric oxide) from urothelium
• Afferent Hypersensitivity: Increased sensitivity of suburothelial afferent nerves to bladder filling
• Sensory Urgency: Enhanced perception of bladder sensation without detrusor overactivity [17]

4. Bladder Outlet Obstruction (Secondary DO)

• Compensatory Hypertrophy: Bladder outlet obstruction (e.g., BPH in men) causes detrusor hypertrophy
• Ischaemia and Remodelling: Chronic obstruction leads to fibrosis, altered innervation
• Overactivity Development: Up to 50-60% of men with BPH develop secondary detrusor overactivity [18]

Causes of Urge Incontinence

---

4. Clinical Presentation

Core Symptoms of OAB Syndrome

The International Continence Society (ICS) defines OAB syndrome by the presence of urgency, with or without urge incontinence, usually accompanied by frequency and nocturia. [2]

Classic Presentations

Clinical Pearl: "Latchkey Incontinence": Urgency/leakage triggered by putting key in the front door lock. This conditioned response is highly specific for OAB and reflects the CNS component of detrusor control. [5]

Other Situational Triggers:

• Sound of running water
• Cold weather or entering a cold environment
• Washing hands
• Arriving home after holding urine during commute
• Anxiety or stress

Distinguishing Stress vs Urge Incontinence

Accurate differentiation is essential for appropriate management.

Mixed Incontinence

• Definition: Coexistence of both stress and urge incontinence symptoms
• Prevalence: 30-40% of women with urinary incontinence have mixed symptoms [10]
• Management Principle: Treat the predominant or most bothersome component first
• Examination Consideration: May require urodynamic studies to guide therapy in refractory cases

Associated Symptoms

---

5. Clinical Examination

History Taking (Structured Approach)

A comprehensive history is the cornerstone of OAB diagnosis.

Key History Components:

1. Symptom Characterization

   • Onset, duration, progression
   • Frequency of micturition (daytime and nighttime)
   • Urgency severity (1-5 scale)
   • Incontinence episodes per day/week
   • Leak volumes (small spurts vs large volumes)
   • Precipitating factors

2. Impact Assessment

   • Quality of life impact (work, social, sleep, sexual function)
   • Pad usage (number per day, type)
   • Fluid restriction behaviour
   • Social avoidance

3. Fluid Intake

   • Total daily volume (aim 1.5-2L)
   • Caffeine intake (coffee, tea, cola, energy drinks)
   • Alcohol consumption
   • Evening fluid intake

4. Obstetric/Gynaecological History

   • Parity, mode of delivery, birth weights
   • Previous pelvic surgery (hysterectomy, prolapse repair, caesarean sections)
   • Menopausal status
   • Oestrogen therapy

5. Medical History

   • Neurological disease (MS, stroke, Parkinson's, spinal injury)
   • Diabetes mellitus
   • Chronic cough (COPD, asthma, smoking)
   • Constipation
   • Mobility issues

6. Medications

   • Diuretics (timing of dose)
   • Anticholinergic burden (cumulative from multiple sources)
   • Alpha-blockers, ACE inhibitors
   • Antidepressants, antipsychotics

7. Red Flag Screening

   • Haematuria (visible or non-visible)
   • Pain (suprapubic, pelvic, loin)
   • Recurrent UTI
   • Neurological symptoms

Physical Examination

Red Flags Requiring Urgent Specialist Referral

---

6. Investigations

First-Line (Primary Care)

Exam Detail: Bladder Diary Analysis (MRCOG Viva Focus):

A 3-day bladder diary is the most valuable non-invasive investigation for OAB. It documents:

• Frequency: Count voids per 24h (> 8 = frequency)
• Nocturia: Number of night-time voids (≥2 clinically significant)
• Urgency: Severity scoring (e.g., 0 = none, 4 = incontinence)
• Incontinence Episodes: Number and volume (estimate)
• Functional Bladder Capacity: Largest single void (normal 300-500ml; less than 200ml suggests reduced capacity)
• Total Fluid Input: Excessive (> 3L) or restricted (less than 1L) intake patterns

Examination Pearl: If functional capacity is consistently less than 200ml with frequent small voids and high urgency scores, this strongly suggests OAB. If capacity is normal (400ml) but occasional large leaks with coughing, suspect mixed incontinence. [9]

Second-Line (Specialist Urogynaecology/Urology)

Exam Detail: Urodynamic Studies—Key Concepts:

Cystometry (Filling Phase):

• Fill bladder at 50ml/min with saline
• Measure detrusor pressure (pdet), abdominal pressure (pabd), total vesical pressure (pves)
• Normal: Pdet remains stable (less than 15cmH2O rise) during filling to capacity (~400-500ml)
• Detrusor Overactivity: Involuntary pdet rise > 15cmH2O during filling, often accompanied by urgency/leakage
• Phasic DO: Intermittent contractions
• Terminal DO: Contraction only at capacity (less clinically significant)

Pressure-Flow Studies (Voiding Phase):

• Assess detrusor contractility and outlet resistance
• Diagnose bladder outlet obstruction (men: Qmax less than 10ml/s with pdet > 40cmH2O)

Limitations: Urodynamics is an artificial environment. Up to 30% of patients with clinical OAB do not demonstrate DO on urodynamics (sensory urgency). Treat the patient's symptoms, not the urodynamic trace. [9]

---

7. Management

Conservative Management (First-Line for All Patients)

Conservative measures should be implemented in all patients before pharmacotherapy. Success rate: 50-80% improvement in symptoms. [19]

Lifestyle Modifications

Bladder Training (Cornerstone of Conservative Management)

Goal: Increase bladder capacity and interval between voids by resisting urgency.

Protocol:

1. Baseline Assessment: Use bladder diary to determine current voiding interval (e.g., every 90 minutes)
2. Set Initial Target: Start with current interval or slightly longer
3. Gradual Extension: Increase voiding interval by 15-30 minutes every 1-2 weeks
4. Urgency Suppression Techniques:
   • Distraction: Count backwards, mental puzzles
   • Pelvic Floor Contractions: 5 quick contractions to inhibit detrusor
   • Breathing Exercises: Deep, slow breathing
   • Pressure: Sit on firm surface, press perineum
5. Goal Interval: Achieve 3-4 hourly voiding (voiding 6-8 times/day)
6. Duration: Minimum 6 weeks (12 weeks optimal)

Success Rate: 60-80% of patients report significant improvement. [19]

Clinical Pearl: Bladder training requires patience and persistence. Patients may initially experience increased urgency and anxiety. Reassure them this is normal. Provide written instructions and telephone support. Success requires motivation and cognitive ability (not suitable for dementia patients).

Pelvic Floor Muscle Training (PFMT)

While primarily used for stress incontinence, PFMT can benefit OAB through urgency suppression via reflex inhibition of detrusor contractions.

Protocol: 8-12 contractions, 3 times daily, for 3 months minimum. Physiotherapist supervision improves adherence.

---

Pharmacotherapy (Second-Line)

Medications are indicated when conservative measures fail or in combination with bladder training.

Antimuscarinic Agents (Anticholinergics)

Mechanism: Block M3 muscarinic receptors on detrusor smooth muscle, reducing involuntary contractions.

Efficacy: Reduce incontinence episodes by 50-60%; reduce urgency and frequency by 20-30%. [20]

Common Side Effects (dose-related):

• Dry mouth (most common, 30-40%)
• Constipation (10-20%)
• Blurred vision (accommodation impairment)
• Urinary retention (rare, risk with PVR > 150ml)
• Cognitive impairment (especially oxybutynin in elderly) [7,8]

Contraindications:

• Narrow-angle glaucoma (relative)
• Myasthenia gravis
• Severe constipation, paralytic ileus
• Urinary retention (PVR > 200ml)

Exam Detail: Anticholinergic Burden and Dementia (High-Yield MRCOG Topic):

The "anticholinergic burden" refers to the cumulative effect of multiple medications with anticholinergic properties. Studies show chronic anticholinergic use (> 3 years) is associated with increased dementia risk (adjusted HR 1.5-1.7). [7,8]

High Anticholinergic Burden Medications: Oxybutynin, tricyclic antidepressants (amitriptyline), first-generation antihistamines (diphenhydramine), antipsychotics.

MRCOG Viva Question: "A 72-year-old woman with OAB is on amitriptyline for neuropathic pain. How would you manage her urinary symptoms?"

Model Answer: "Avoid adding anticholinergic burden. Consider mirabegron (beta-3 agonist) as first-line pharmacotherapy. Review indication for amitriptyline—could it be switched to an alternative with lower anticholinergic effect (e.g., duloxetine, pregabalin)? Emphasize bladder training and conservative measures."

Beta-3 Adrenergic Agonist

Efficacy: Non-inferior to antimuscarinics; reduces incontinence episodes by 50-55%. [21]

Side Effects:

• Hypertension (5-10% experience mild increase; monitor BP)
• Headache
• Nasopharyngitis
• Urinary retention (rare)

Contraindications:

• Severe uncontrolled hypertension (SBP > 180mmHg)
• End-stage renal disease (eGFR less than 15)

Advantages over Antimuscarinics:

• Better cognitive safety profile (does not cross BBB)
• Better tolerated (lower discontinuation rate)
• Can be combined with anticholinergic if monotherapy inadequate [22]

Combination Therapy

Anticholinergic + Beta-3 Agonist: For patients with inadequate response to monotherapy. Combination (e.g., solifenacin 5mg + mirabegron 50mg) improves efficacy by 20-30% over monotherapy. [22]

Vaginal Oestrogen (in Postmenopausal Women):

• Low-dose vaginal oestrogen (cream, pessary, ring) improves urogenital atrophy
• May reduce urgency and frequency in women with atrophic vaginitis
• Systemic absorption minimal; safe in most women
• Not licensed specifically for OAB but useful adjunct

---

Third-Line (Specialist Procedures)

Indicated for patients with refractory OAB failing conservative and pharmacological management.

Intradetrusor Botulinum Toxin A (OnabotulinumtoxinA)

Mechanism: Blocks acetylcholine release at neuromuscular junction, causing flaccid paralysis of detrusor muscle.

Procedure:

• Cystoscopic injection of 100 units (dispersed in 20 sites across detrusor, sparing trigone)
• Outpatient procedure under local or general anaesthesia
• Duration of effect: 6-9 months (median 7 months)

Efficacy: 60-70% achieve > 50% reduction in incontinence episodes; 20-30% achieve complete dryness. [23]

Side Effects:

• Urinary retention: 5-10% require clean intermittent self-catheterization (CISC) for 4-12 weeks
• UTI: 20-30% (especially if CISC required)
• Transient haematuria

Patient Selection:

• Refractory OAB despite optimal medical therapy
• Willing to accept risk of CISC
• No significant PVR at baseline (less than 100ml)

NICE Guidance: Approved for OAB refractory to antimuscarinics or if antimuscarinics contraindicated. [24]

Sacral Neuromodulation (SNM)

Mechanism: Implanted pulse generator delivers electrical stimulation to S3 nerve root, modulating bladder reflex pathways.

Procedure (Two-Stage):

1. Stage 1 (Test Phase): Percutaneous nerve evaluation (PNE) or staged lead placement; external stimulator worn for 1-2 weeks
2. Stage 2 (Permanent Implant): If > 50% improvement in test phase, implant permanent pulse generator (IPG) in gluteal region

Efficacy: 60-70% of patients respond to test stimulation; of those, 70-80% maintain improvement at 5 years. [25]

Indications:

• Refractory OAB (failed conservative, medical, botulinum toxin)
• Non-obstructive urinary retention
• Faecal incontinence (also licensed)

Complications:

• Lead migration (5-10%)
• Infection (3-5%)
• Need for revision surgery (10-15% at 5 years)
• Device explantation (10-15% at 5 years)

NICE Guidance: Approved for refractory OAB after multidisciplinary team (MDT) assessment. [24]

Percutaneous Tibial Nerve Stimulation (PTNS)

Mechanism: Transcutaneous or percutaneous stimulation of posterior tibial nerve (L4-S3 nerve roots) modulates bladder reflexes.

Protocol: Weekly 30-minute sessions for 12 weeks, then maintenance (monthly sessions).

Efficacy: 50-60% report improvement; less effective than SNM but non-invasive. [26]

Advantages: Non-surgical, minimal side effects, office-based procedure.

Limitations: Requires ongoing regular sessions; effect wanes if treatment stopped.

---

Management Algorithm

OAB Suspected (Urgency ± Incontinence)
          ↓
RED FLAGS? → YES → Urgent Specialist Referral
          ↓ NO
Investigations: Urinalysis, MSU, Bladder Diary, PVR
          ↓
FIRST-LINE (6-12 weeks)
- Lifestyle modification (caffeine, fluids, weight)
- Bladder training
- PFMT
          ↓
Inadequate Response?
          ↓
SECOND-LINE (Pharmacotherapy)
- Anticholinergic (solifenacin/tolterodine/trospium)
  OR
- Beta-3 agonist (mirabegron) [especially if elderly]
          ↓
Inadequate Response after 3 months?
          ↓
Optimize Dose / Try Alternative Agent / Combination Therapy
          ↓
Still Inadequate Response?
          ↓
SPECIALIST REFERRAL (Urogynaecology/Urology)
Consider:
- Urodynamic studies
- THIRD-LINE PROCEDURES:
  • Botulinum toxin A
  • Sacral neuromodulation
  • Percutaneous tibial nerve stimulation

---

8. Complications

---

9. Prognosis and Outcomes

Treatment Outcomes

Long-Term Prognosis

• Chronic Condition: OAB is typically a chronic, relapsing-remitting condition requiring long-term management. Few patients experience spontaneous resolution.
• Medication Adherence: Only 25-30% of patients continue anticholinergics beyond 12 months due to side effects or perceived lack of efficacy. [20]
• Quality of Life: With appropriate treatment, > 70% of patients report significant QoL improvement.
• Progressive Therapy: Many patients require escalation from conservative → pharmacotherapy → interventional procedures over time.

---

10. Evidence and Guidelines

Key Guidelines

Landmark Studies

Exam Detail: 1. EPIC Study (2006): Multinational epidemiological study (n=19,165) established OAB prevalence at 11.8% globally, with strong age association. [3]

2. Mirabegron Systematic Review (Cochrane 2018): Meta-analysis of 10 RCTs (n=9000+) showed mirabegron reduces incontinence episodes similarly to antimuscarinics but with better tolerability and persistence. [21]

3. Anticholinergic Burden and Dementia (Gray et al., JAMA 2015): Cohort study (n=3434) showed chronic high-dose anticholinergic use associated with increased dementia risk (adjusted HR 1.54 for ≥3 years' use). [7]

4. Botulinum Toxin vs Anticholinergics (Visco et al., NEJM 2012): RCT (n=247) showed onabotulinumtoxinA 100U superior to anticholinergics for refractory OAB, with 70% vs 50% improvement, but 5% risk of retention. [23]

5. Sacral Neuromodulation Long-Term Outcomes (Siegel et al., J Urol 2018): 5-year follow-up showed sustained therapeutic success in 82% of OAB patients, with 15% requiring device revision. [25]

---

11. Examination Focus (MRCOG/Urology Viva)

High-Yield Viva Topics

Exam Detail: #### Viva Question 1: "A 68-year-old woman presents with urge incontinence. She is on amitriptyline for neuropathic pain and diphenhydramine for insomnia. How would you manage her OAB?"

Model Answer:

"This patient has a high anticholinergic burden from amitriptyline and diphenhydramine, which increases her risk of cognitive impairment and potentially worsens her bladder symptoms through anticholinergic effects.

My approach would be:

1. Medication Review: Discuss with GP switching amitriptyline to duloxetine or pregabalin (lower anticholinergic burden) and diphenhydramine to melatonin or sleep hygiene measures.
2. Conservative First-Line: Emphasize bladder training, caffeine reduction, timed voiding, fluid modification.
3. Pharmacotherapy: Avoid anticholinergics. First-line: Mirabegron 50mg OD (no anticholinergic effects, safe cognitive profile).
4. Monitor: Blood pressure (mirabegron can increase BP by 5-10mmHg).
5. Follow-Up: Review at 8-12 weeks; if inadequate response, consider specialist referral for urodynamics and advanced therapies (botulinum toxin, SNM)."

---

Viva Question 2: "What is the difference between OAB and detrusor overactivity?"

Model Answer:

"OAB is a symptom syndrome, while detrusor overactivity is a urodynamic observation. They are not synonymous.

OAB: Defined by the ICS as urgency, with or without urge incontinence, usually with frequency and nocturia, in the absence of infection or pathology. It's a clinical diagnosis based on symptoms.

Detrusor Overactivity (DO): A urodynamic finding of involuntary detrusor contractions (> 15cmH2O pdet rise) during bladder filling on cystometry.

Key Point: Up to 30% of patients with clinical OAB symptoms do not have DO on urodynamics (sensory urgency). Conversely, some asymptomatic individuals may show DO. We treat the patient's symptoms, not the urodynamic trace. Urodynamics are reserved for diagnostic uncertainty, failed treatment, or pre-surgical assessment."

---

Viva Question 3: "Describe the mechanism of action of botulinum toxin in OAB."

Model Answer:

"Botulinum toxin A is a neurotoxin that inhibits acetylcholine release at the neuromuscular junction by cleaving SNAP-25 protein required for vesicle fusion.

In the bladder:

1. Injected into detrusor muscle (100 units distributed across 20 sites, sparing trigone)
2. Causes flaccid paralysis of detrusor smooth muscle
3. Reduces involuntary detrusor contractions (detrusor overactivity)
4. Also affects sensory afferents: reduces release of neurotransmitters (ATP, substance P) from urothelium, decreasing bladder sensation

Efficacy: 60-70% achieve > 50% reduction in incontinence; effect lasts 6-9 months (median 7).

Key Side Effect: Urinary retention in 5-10% of patients, requiring clean intermittent self-catheterization for 4-12 weeks. Patient must be counselled about this risk and willing to perform CISC if needed."

---

12. Patient / Layperson Explanation

What is Overactive Bladder (OAB)?

Overactive bladder is a common condition where your bladder suddenly contracts (squeezes) when it shouldn't, giving you a very strong urge to urinate. This can happen even when your bladder isn't full. Sometimes, the urge is so strong that you may leak urine before you can get to the toilet—this is called urge incontinence.

What are the Symptoms?

• Sudden, strong urge to urinate: You feel you need to go RIGHT NOW, and it's hard to hold it.
• Frequent urination: Going to the toilet more than 8 times a day.
• Getting up at night: Waking up 2 or more times during the night to urinate.
• Leaking urine: Sometimes not making it to the toilet in time.

What Causes OAB?

In most cases, we don't know the exact cause (called "idiopathic"). Your bladder muscle (called the detrusor) contracts involuntarily. This can happen with:

• Aging (more common in people over 65)
• Neurological conditions (like stroke, Parkinson's disease, or multiple sclerosis)
• Obesity
• Diabetes

How is OAB Diagnosed?

Your doctor will:

• Ask about your symptoms and how they affect your life
• Ask you to keep a bladder diary for 3 days (record how often you go, how much you drink, and when you leak)
• Do a urine test to rule out infection
• Examine you to check for other problems

How is OAB Treated?

Treatment usually starts simple and progresses if needed:

1. Lifestyle Changes (First Step)

• Reduce caffeine: Coffee, tea, and cola can irritate your bladder.
• Manage your fluids: Aim for 6-8 glasses of water a day (not too much, not too little).
• Lose weight: If overweight, even a 5-10% weight loss can help.
• Avoid alcohol: Especially in the evening.

2. Bladder Training (Very Important!)

This teaches your bladder to hold more urine and go less often:

• Set a schedule for toilet trips (e.g., every 2 hours)
• When you feel the urge, try to wait a few extra minutes before going
• Gradually increase the time between toilet visits
• Use distraction techniques (count backwards, breathe deeply)
• This takes 6-12 weeks, but 60-80% of people improve!

3. Medications (If Lifestyle Changes Aren't Enough)

Your doctor may prescribe:

• Anticholinergics (e.g., solifenacin, tolterodine): These relax your bladder muscle. Side effects can include dry mouth and constipation.
• Mirabegron: A different type of medication that relaxes the bladder but doesn't cause dry mouth or cognitive problems. It's often preferred for older adults.

4. Advanced Treatments (For Severe Cases)

If medications don't work, your doctor may refer you to a specialist who can offer:

• Botox injections: Injected into your bladder to stop involuntary contractions (lasts 6-9 months).
• Nerve stimulation (Sacral Neuromodulation): A small device implanted under your skin sends electrical signals to control your bladder.

Will I Get Better?

Yes! Most people improve significantly with treatment:

• 60-80% improve with bladder training alone
• 50-60% improve with medications
• Advanced treatments help 60-70% of people who haven't responded to other treatments

OAB is a chronic condition, meaning it may come and go over time, but with the right treatment and lifestyle changes, you can manage it well and improve your quality of life.

Important: When to See a Doctor Urgently

See your doctor immediately if you have:

• Blood in your urine
• Severe pain in your pelvis or abdomen
• Numbness in your genital area or buttocks
• New weakness in your legs
• Frequent urine infections

---

13. References

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-178. DOI: 10.1002/nau.10052

2. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21(1):5-26. DOI: 10.1007/s00192-009-0976-9

3. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306-1315. DOI: 10.1016/j.eururo.2006.09.019

4. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327-336. DOI: 10.1007/s00345-002-0301-4

5. Coyne KS, Sexton CC, Thompson CL, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int. 2009;104(3):352-360. DOI: 10.1111/j.1464-410X.2009.08427.x

6. Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci. 2008;9(6):453-466. DOI: 10.1038/nrn2401

7. Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401-407. DOI: 10.1001/jamainternmed.2014.7663

8. Richardson K, Fox C, Maidment I, et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018;361:k1315. DOI: 10.1136/bmj.k1315

9. Nager CW, Brubaker L, Litman HJ, et al. A randomized trial of urodynamic testing before stress-incontinence surgery. N Engl J Med. 2012;366(21):1987-1997. DOI: 10.1056/NEJMoa1113595

10. Minassian VA, Stewart WF, Wood GC. Urinary incontinence in women: variation in prevalence estimates and risk factors. Obstet Gynecol. 2008;111(2 Pt 1):324-331. DOI: 10.1097/01.AOG.0000267220.48987.17

11. Subak LL, Wing R, West DS, et al. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med. 2009;360(5):481-490. DOI: 10.1056/NEJMoa0806375

12. Jura YH, Townsend MK, Curhan GC, Resnick NM, Grodstein F. Caffeine intake, and the risk of stress, urgency and mixed urinary incontinence. J Urol. 2011;185(5):1775-1780. DOI: 10.1016/j.juro.2011.01.003

13. Coyne KS, Wein AJ, Tubaro A, et al. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int. 2009;103 Suppl 3:4-11. DOI: 10.1111/j.1464-410X.2009.08371.x

14. Perry S, McGrother CW, Turner K. An investigation of the relationship between anxiety and depression and urge incontinence in women: development of a psychological model. Br J Health Psychol. 2006;11(Pt 3):463-482. DOI: 10.1348/135910705X60733

15. Brading AF. A myogenic basis for the overactive bladder. Urology. 1997;50(6A Suppl):57-67. DOI: 10.1016/s0090-4295(97)00591-8

16. de Groat WC, Yoshimura N. Afferent nerve regulation of bladder function in health and disease. Handb Exp Pharmacol. 2009;(194):91-138. DOI: 10.1007/978-3-540-79090-7_4

17. Birder LA, Andersson KE. Urothelial signaling. Physiol Rev. 2013;93(2):653-680. DOI: 10.1152/physrev.00030.2012

18. Abrams P, Dunn M, George N. Urodynamic findings in chronic retention of urine and their relevance to results of surgery. Br Med J. 1978;2(6147):1258-1260. DOI: 10.1136/bmj.2.6147.1258

19. Wallace SA, Roe B, Williams K, Palmer M. Bladder training for urinary incontinence in adults. Cochrane Database Syst Rev. 2004;(1):CD001308. DOI: 10.1002/14651858.CD001308.pub2

20. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543-562. DOI: 10.1016/j.eururo.2008.06.047

21. Cui Y, Zong H, Yang C, Yan H, Zhang Y. The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. Int Urol Nephrol. 2014;46(1):275-284. DOI: 10.1007/s11255-013-0509-9

22. Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. 2015;67(3):577-588. DOI: 10.1016/j.eururo.2014.02.012

23. Visco AG, Brubaker L, Richter HE, et al. Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence. N Engl J Med. 2012;367(19):1803-1813. DOI: 10.1056/NEJMoa1208872

24. National Institute for Health and Care Excellence. Urinary incontinence and pelvic organ prolapse in women: management. NICE guideline [NG123]. Published April 2019. Updated June 2019. Available at: https://www.nice.org.uk/guidance/ng123

25. Siegel S, Noblett K, Mangel J, et al. Five-year followup results of a prospective, multicenter study of patients with overactive bladder treated with sacral neuromodulation. J Urol. 2018;199(1):229-236. DOI: 10.1016/j.juro.2017.07.010

26. Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183(4):1438-1443. DOI: 10.1016/j.juro.2009.12.036